Downregulation of the Rho GTPase signaling pathway is involved in the microRNA‐138‐mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma
Tumor metastasis is the dominant cause of death in cancer patients, including patients with oral tongue squamous cell carcinoma (TSCC). Previously, we reported that reduced miR‐138 level is correlated with enhanced metastatic potential in TSCC cells. Here, we demonstrate that miR‐138 suppresses TSCC...
Gespeichert in:
Veröffentlicht in: | International journal of cancer 2010-08, Vol.127 (3), p.505-512 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Tumor metastasis is the dominant cause of death in cancer patients, including patients with oral tongue squamous cell carcinoma (TSCC). Previously, we reported that reduced miR‐138 level is correlated with enhanced metastatic potential in TSCC cells. Here, we demonstrate that miR‐138 suppresses TSCC cell migration and invasion by regulating 2 key genes in the Rho GTPase signaling pathway: RhoC and ROCK2. Direct targeting of miR‐138 to specific sequences located in the 3′‐untranslated regions of both RhoC and ROCK2 mRNAs was confirmed using luciferase reporter gene assays. Ectopic transfection of miR‐138 reduced the expression of both RhoC and ROCK2 in TSCC cells. These reduced expressions, in consequence, led to the reorganization of the stress fibers and the subsequent cell morphology change to a round bleb‐like shape as well as the suppression of cell migration and invasion. In contrast, knockdown of miR‐138 in TSCC cells enhanced the expression of RhoC and ROCK2, which resulted in an altered, elongated cell morphology, enhanced cell stress fiber formation and accelerated cell migration and invasion. Taken together, our results suggest that miR‐138 plays an important role in TSCC cell migration and invasion by concurrently targeting RhoC and ROCK2, and miR‐138 may serve as a novel therapeutic target for TSCC patients at risk of metastatic disease. |
---|---|
ISSN: | 0020-7136 1097-0215 |
DOI: | 10.1002/ijc.25320 |